We work to identify and optimize value throughout the transaction lifecycle, from initial diligence to final exit. Having worked with financial buyers as well as corporate entities, A&M provides objective analysis, improves asset performance, and ensures that synergies and the market impact of transactions are clearly defined and realized.
Our professionals assist with buy and sell-side decisions, integrating the organization, processes and technology, and designing / executing plans to accomplish objectives as quickly as possible. Our deep experience in many specific industry segments in healthcare means we don’t have to scale a learning curve; we focus on the issues that matter most. We often bridge from diligence to post closing support to provide management the necessary bandwidth to accelerate their path to results.
Rely on us for help with:
- Integrated Buy and Sell Side Due Diligence – Operations, Technology, Financial, Tax
- Merger Integration Planning and Synergy Analysis
- Merger Program Management Office
- Value Creation Plan Development and Implementation
- Sell Side preparation and diligence
- Carve out planning, assessment and Standalone readiness
- Real Estate Advisory
- Financial Modeling
- Deal Structuring
- Capital Sourcing
Please click here for more information.
Contract Research Organisations M&A Market
March 28, 2025
Rising cost pressures, stricter regulatory demands and advancements in emerging therapeutics are intensifying competition within the industry. These dynamics are fuelling the demand for greater efficiency in development lifecycles, creating significant opportunities for outsourced providers like Contract Research Organisations (CROs).
Healthcare Workforce Predictions for 2025
March 19, 2025
The healthcare landscape in 2025 is marked by a complex interplay of financial pressures, persistent workforce shortages, and rapid technological advancements. While healthcare providers have stabilized post-pandemic, they face shrinking revenues coupled with escalating workforce expense, which now comprise a significant portion of total expenses.
Mass General Brigham is Redefining ROI Through the Lens of its Mission to Improve Human Health
March 18, 2025
How do you fundamentally redefine “ROI”? Niyum Gandhi, CFO of Mass General Brigham, the largest employer in New England and the largest medical research organization in the world, shares about his Moonshot to do just that.
The Clock is Ticking: Why Health Plans Must Act Now to Maximize Star Ratings Before the 2026 HEI Update
March 12, 2025
The October 2026 Star Ratings release presents both an opportunity and a challenge for health plans as they navigate uncertain Health Equity Index (HEI) changes. With evolving CMS equity-focused metrics, shifting data collection requirements, and potential weighting adjustments, health plans must take immediate action to optimize their Star Ratings before potential regulatory shifts in 2027.